Abstract 27P
Background
With the development of immune checkpoint inhibitors (ICI), microsatellite instability (MSI) has become an important biomarker. While large multigene hybrid capture next-generation sequencing (NGS) panels are highly accurate in detecting MSI, the sensitivity of small amplicon-based panels is unknown.
Methods
Next-generation sequencing (NGS) was performed on FFPE samples from patients with any stage colorectal cancer (CRC) using the Solo Atlas Pro amplicon panel covering 38 genes and 39 mononucleotide short tandem repeats for MSI analysis. 5-loci polymerase chain reaction (PCR)-based MSI analysis was used as a reference method. MSI by NGS was estimated based on the distribution of k-mers. Statistical analysis was performed using Cohen’s kappa (к), Mann Whitney and Fisher’s exact test.
Results
A total of 160 samples were analyzed using NGS and PCR. Median coverage was 2352x (range, 238-28447х), MAPD – 0.368 (range, 0.236-0.731). Based on PCR results, 42 (46.25%) samples were MSI, 118 (73.75%) – MSS. Based on NGS results, 40 (25%) samples were MSI, 120 (75%) were MSS. NGS and PCR were concordant in 98.75% (158/160) of samples (к=0.97). Sensitivity of NGS was 95.24% (95% CI, 83.84%-99.42%), specificity – 100.00% (96.92%-100.00%), accuracy – 98.75% (95.56%-99.85%). All NGS false positives cases had suboptimal FFPE quality, suggested by absence of any somatic mutations identified. MSI samples had a significantly higher amount of somatic mutations than MSS samples (median, 3 vs 1, p<0.0001). In silico mixing of the sequencing data of 11 MSI samples demonstrated that the minimal sample fraction with the detectable MSI was 0.5%; at 2.5% MSI was detectable in all samples.
Conclusions
The Atlas Pro amplicon panel demonstrates high concordance with PCR and is highly sensitive in detecting MSI in CRC samples.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation (Grant №22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks
Presenter: Nicola Occelli
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Onconaut: A precision medicine platform for oncology therapies
Presenter: Altuna Akalin
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis
Presenter: Daniel Arruda Navarro Albuquerque
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
Presenter: Sofia Merajver
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - Circulating tumor cells and circulating tumor DNA detection in colorectal cancer stage III patients receiving three or six months of adjuvant treatment
Presenter: Asimina Koulouridi
Session: Cocktail & Poster Display session
Resources:
Abstract
10P - Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744
Presenter: Ahmed Mokhtar
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Prognostic value of PD-L1 expression and neutrophil-to-lymphocyte ratio to neoadjuvant chemo-immunotherapy in muscle-invasive urothelial carcinoma patients from the AURA trial
Presenter: Jeremy Blanc
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - Methylation of BRCA1 and RAD51C promoters determined by droplet digital PCR predicts homologous repair deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study in paired FFPE and plasma samples and the ICL ovarian cohort
Presenter: Cassandra Michel
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - SLFN11 detection in patients with small cell lung cancer treated with lurbinectedin: A retrospective translational analysis
Presenter: Daniela Scattolin
Session: Cocktail & Poster Display session
Resources:
Abstract